Serum pentraxin-3 levels are associated with the severity of metabolic syndrome

Medical Principles and Practice

Volumn 22, Issue 3, 2013, Pages 274-279

  Karakas, Mehmet Fatih ^a   Buyukkaya, Eyup ^a   Kurt, Mustafa ^a   Motor, Sedat ^a   Akcay, Adnan Burak ^a   Karakas, Esra ^a   Buyukkaya, Şule ^b   Sen, Nihat ^a  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b ANTAKYA STATE HOSPITAL   (Turkey)

Author keywords

High sensitivity C reactive protein; Inflammation; Metabolic syndrome; Pentraxin 3

Indexed keywords

C REACTIVE PROTEIN; PENTRAXIN 3;

ADULT; ARTICLE; BODY MASS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; BODY WEIGHTS AND MEASURES; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FEMALE; HUMANS; INFLAMMATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PATIENT ACUITY; PROSPECTIVE STUDIES; RANDOM ALLOCATION; SERUM AMYLOID P-COMPONENT;

EID: 84876050060     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000343904     Document Type: Article

References (26)

1. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438
2. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I: Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106: 1439-1441
3. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497
4. Williams S, Cunningham E, Pories WJ: Surgical treatment of metabolic syndrome. Med Princ Pract 2012; 21: 301-309
5. Sorkhou EI, Al-Qallaf B, Al-Namash HA, Ben-Nakhi A, Al-Batish MM, Habiba SA: Prevalence of metabolic syndrome among hypertensive patients attending a primary care clinic in Kuwait. Med Princ Pract 2004; 13: 39-42
6. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW: C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972-978
7. Ridker PM, Buring JE, Cook NR, Rifai N: Creactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14,719 initially healthy American women. Circulation 2003; 107: 391-397
8. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695
9. Brown DW, Giles WH, Croft JB: White blood cell count: An independent predictor of coronary heart disease mortality among a national cohort. J Clin Epidemiol 2001; 54: 316-322
10. Abderrahim-Ferkoune A, Bezy O, Chiellini C, Maffei M, Grimaldi P, Bonino F, Moustaid-Moussa N, Pasqualini F, Mantovani A, Ailhaud G, et al: Characterization of the long pentraxin PTX3 as a TNFalpha-induced secreted protein of adipose cells. J Lipid Res 2003; 44: 994-1000
11. Fazzini F, Peri G, Doni A, Dell'Antonio G, Dal Cin E, Bozzolo E, D'Auria F, Praderio L, Ciboddo G, Sabbadini MG et al: PTX3 in small-vessel vasculitides: An independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 2001; 44: 2841-2850
12. Amit M, Carpenter MK, Inokuma MS, Chiu CP, Harris CP, Waknitz MA, Itskovitz-Eldor J, Thomson JA: Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. Dev Biol 2000; 227: 271-278
13. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, Vago L, Pasqualini F, Signorini S, Soldateschi D, et al: Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004; 110: 2349-2354
14. Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B, Mantovani A: Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 2001; 29: 1404-1407
15. Bevelacqua V, Libra M, Mazzarino MC, Gangemi P, Nicotra G, Curatolo S, Massimino D, Plumari A, Merito P, Valente G, et al: Long pentraxin 3: A marker of inflammation in untreated psoriatic patients. Int J Mol Med 2006; 18: 415-423
16. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, Sagara M, Miyamoto K, Satoh H, Kohno I, et al: Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007; 27: 161-167
17. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, Sagara M, Kubota I: Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008; 155: 75-81
18. Matsubara J, Sugiyama S, Nozaki T, Sugamura K, Konishi M, Ohba K, Matsuzawa Y, Akiyama E, Yamamoto E, Sakamoto K, et al: Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol 2011; 57: 861-869
19. Frayn KN: Insulin resistance, impaired postprandial lipid metabolism and abdominal obesity. A deadly triad. Med Princ Pract 2002; 11(suppl 2):31-40
20. Zanetti M, Bosutti A, Ferreira C, Vinci P, Biolo G, Fonda M, Valente M, Cattin L, Guarnieri G, Barazzoni R: Circulating pentraxin. levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile. Clin Exp Med 2009; 9: 243-248
21. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA et al: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913-919
22. Ridker PM, Pare G, Parker A, Zee RY, Danik JS, Buring JE, Kwiatkowski D, Cook NR, Miletich JP, Chasman DI: Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet 2008; 82: 1185-1192
23. Klouche M, Peri G, Knabbe C, Eckstein HH, Schmid FX, Schmitz G, Mantovani A: Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis 2004; 175: 221-228
24. Breviario F, d'Aniello EM, Golay J, Peri G, Bottazzi B, Bairoch A, Saccone S, Marzella R, Predazzi V, Rocchi M et al: Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem 1992; 267: 22190-22197
25. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM: Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2009; 29: 594-599
26. Matsui S, Ishii J, Kitagawa F, Kuno A, Hattori K, Ishikawa M, Okumura M, Kan S, Nakano T, Naruse H, et al: Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 2010; 210: 220-225.